Dako and Quintiles form alliance to speed development of personalized medicine

02-Nov-2010 - Denmark

Dako and Quintiles announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca in the development of one of its leading oncology compounds.

"Quintiles and Dako share the same goals for speed, quality and efficiency," said Thomas Wollman, Senior Vice President, Quintiles Global Central Laboratories. "By pairing our core competencies in translational medicine, biomarker discovery and managing clinical trials with Dako's expertise in companion diagnostics, we can help physician investigators select the right patients for the right clinical trials, thereby accelerating the development of personalized oncology therapies for our customers in the New Health landscape."

As part of the alliance, Dako will develop cancer diagnostic tests, and Quintiles will conduct the tests as part of the clinical validation. Both Dako and Quintiles will continue to work independently with biopharmaceutical companies and service providers in the industry.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Last viewed contents

Metobolomics uncovers key indicators of nonalcoholic fatty liver disease - Impaired oxidation in liver associated with progression to NASH

“Viral relicts” in the Genome Could Fuel Neurodegeneration - Researchers see ancient genes as potential targets for dementia treatment

“Viral relicts” in the Genome Could Fuel Neurodegeneration - Researchers see ancient genes as potential targets for dementia treatment

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

Artificial intelligence recognizes heart disease by the sound of the voice - AI from a Berlin start-up is used for this purpose

Artificial intelligence recognizes heart disease by the sound of the voice - AI from a Berlin start-up is used for this purpose

Analytica USA: New meeting place for the laboratory industry - Premiere in September 2025 in Columbus, Ohio

Analytica USA: New meeting place for the laboratory industry - Premiere in September 2025 in Columbus, Ohio

MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease - Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

Eppendorf SE and DataHow AG announce strategic collaboration to advance bioprocess data management

Eppendorf SE and DataHow AG announce strategic collaboration to advance bioprocess data management

Alzheimer’s: modulation of cell membrane influences formation of amyloid-β - Adding long-chain fatty acids can thicken cell membranes and alter the activity of a key enzyme

Alzheimer’s: modulation of cell membrane influences formation of amyloid-β - Adding long-chain fatty acids can thicken cell membranes and alter the activity of a key enzyme

Health tech startup Carelane sets new standards for clinical research with AI-driven, end-to-end platform - Seed funding of EUR 2.6 million led by Vorwerk Ventures

Health tech startup Carelane sets new standards for clinical research with AI-driven, end-to-end platform - Seed funding of EUR 2.6 million led by Vorwerk Ventures

StratifAI joins with MSK iHub Challenge Cohort to advance validation of Polaris™ through access to world-class clinical datasets

StratifAI joins with MSK iHub Challenge Cohort to advance validation of Polaris™ through access to world-class clinical datasets

InterMed Discovery and Axxam Announce Joint Research Agreement for the Identification of Novel Natural Functional Ingredients